Human Genome, Gentium in spotlight

Human Genome Sciences is the lead gainer among the larger-cap drug-stock issues in early activity, moving on news that analysts at Jesup and Lamont have initiated coverage of the stock with a buy rating.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.